Characteristic | Unadjusted HR (95 % CI) | P value |
---|---|---|
Sociodemographic characteristics | ||
Pediatric casea | 0.36 (0.12–1.14) | 0.082 |
Female gender | 0.65 (0.45–0.95) | 0.025 |
Unemployed | 2.95 (2.09–4.18) | <0.001 |
Did not begin secondary level education, n = 1700 | 1.08 (0.71–1.65) | 0.712 |
Substance abuse, n = 1699b | 1.72 (1.23–2.41) | 0.002 |
Comorbidities | ||
HIV positive | 5.99 (4.18–8.59) | <0.001 |
Diabetes mellitus | 0.57 (0.26–1.22) | 0.146 |
TB history and risk exposures | ||
Previously treated for TB | 1.62 (0.90–2.93) | 0.110 |
Prior incarceration, n = 1695c | 1.07 (0.52–2.19) | 0.854 |
Recent hospitalization for >15 daysc | 4.13 (1.53–11.2) | 0.005 |
Healthcare occupational exposurec,d | 0.15 (0.02–1.08) | 0.060 |
Clinical presentation, all patients | ||
Duration of symptoms >3 months before DST solicited, n = 1690 | 0.99 (0.70–1.41) | 0.970 |
Weight loss, n = 1698 | 2.99 (1.65–5.43) | <0.001 |
Able to perform ADLs | 0.15 (0.10–0.21) | <0.001 |
Low BMI, n = 1693e | 2.38 (1.70–3.35) | <0.001 |
Dyspnea, n = 1698 | 2.90 (2.04–4.11) | <0.001 |
Hemoptysis, n = 1699 | 0.52 (0.21–1.26) | 0.147 |
No CXR performed | 1.59 (0.65–3.88) | 0.312 |
Abnormal CXR, n = 1651 | 0.60 (0.35–1.02) | 0.061 |
Cavitary disease, n = 1651 | 0.87 (0.61–1.24) | 0.446 |
Extrapulmonary TB | 1.51 (0.82–2.80) | 0.188 |
Clinical presentation, HIV positive patients only | ||
Receiving ART at baseline, n = 187 | 0.72 (0.28–1.82) | 0.482 |
Receiving cotrimoxazole at baseline, n = 187 | 0.53 (0.21–1.36) | 0.188 |
No CD4 performed, n = 187 | 1.25 (0.60–2.61) | 0.550 |
Microbiologic data | ||
Baseline bacteriologically unconfirmed TB diagnosisf | 2.02 (1.14–3.59) | 0.016 |
Baseline sputum AFB smear positive, n = 1669 | 0.87 (0.53–1.43) | 0.589 |
Baseline MDR-TB, n = 1211 | 1.10 (0.73–1.65) | 0.658 |
No baseline DST result | 1.02 (0.70–1.51) | 0.906 |
Treatment course | ||
Received second line drugs during studyg | 0.84 (0.57–1.23) | 0.376 |
Non-adherence, n = 1689h | 0.84 (0.56–1.25) | 0.381 |